A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
Publication information:
Ryan C, Brander D, Barr P, Tyekucheva S, Hackett L, Collins M, Fernandes S, Ren Y, Zhou Y, McDonough M, Walker H, McEwan M, Abramson J, Jacobsen E, LaCasce A, Fisher D, Brown J, Davids M. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Leukemia. 2023;(Jan 30).